ARHGAP19: A Potential Drug Target and Biomarker (G84986)

Target Name: ARHGAP19

NCBI ID: G84986

ARHGAP19

ARHGAP19: A Potential Drug Target and Biomarker

ARHGAP19 is a protein that is expressed in various tissues and cells in the human body. It is a member of the GTPase-activating protein (GAP) family, which is a subgroup of the protein kinase superfamily. GAPs are a family of proteins that play a critical role in intracellular signaling, by regulating the activity of various signaling pathways. ARHGAP19 is one of the GAPs that is known to interact with the protein RhoA, which is a GTPase that is involved in cell signaling.

The discovery of ARHGAP19

The study of ARHGAP19 was first reported in 2007, by a research team at the University of California, San Diego. The authors identified ARHGAP19 as a new protein that was expressed in various tissues and cells, including muscle, heart, and brain. They also found that the protein was able to interact with RhoA, and that this interaction was critical for the activity of RhoA.

Since then, several studies have confirmed the importance of ARHGAP19 in intracellular signaling. For example, researchers have found that ARHGAP19 is involved in the regulation of muscle growth and differentiation, and that it is able to alter the activity of several signaling pathways, including the TGF-β pathway.

Drug targeting and biomarker potential

The potential drug targeting of ARHGAP19 is an attractive idea, given its involvement in intracellular signaling. Several studies have suggested that ARHGAP19 may be a good candidate for drug targeting, either alone or in combination with other drugs. For example, researchers have found that inhibiting the activity of ARHGAP19 may be a useful way to treat a variety of diseases, including cancer, neurodegenerative diseases, and muscle-related conditions.

In addition to its potential as a drug target, ARHGAP19 may also be used as a biomarker. The GAP family of proteins is known for its ability to regulate the activity of various signaling pathways, and this can be used as a potential biomarker. Researchers have suggested that ARHGAP19 may be a good candidate for use as a biomarker for a variety of conditions, including cancer, neurodegenerative diseases, and muscle-related conditions.

Conclusion

ARHGAP19 is a protein that has important involvement in intracellular signaling. Its interaction with the protein RhoA makes it a potential drug target, and its involvement in the regulation of muscle growth and differentiation makes it a promising candidate for use as a biomarker. Further research is needed to fully understand the role of ARHGAP19 in intracellular signaling and its potential as a drug target and biomarker.

Protein Name: Rho GTPase Activating Protein 19

Functions: GTPase activator for the Rho-type GTPases by converting them to an inactive GDP-bound state

The "ARHGAP19 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARHGAP19 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets